The Antibody Shared Resource provides a central site for the production of monoclonal and polyclonal antibodies by CSHL Cancer Center personnel. The purpose of this Shared Resource is to provide the resources and expertise to generate these valuable reagents in a highly efficient and cost-effective manner. In the ease of monoclonal antibodies, CSHL Cancer Center scientists provide specific antigens, and the Shared Resource personnel handle all stages of immunization, fusion, primary screening of hybridomas, cell culture, single-cell cloning, freezing and storage of hybridoma lines, and large-scale production of monoclonal antibodies in cell culture or in vivo. Immunization, test bleeds, and production of ascites fluids are coordinated with the personnel of the Animal Shared Resource. Specialized monoclonal antibody screens are closely coordinated with individual scientists. Polyclonal antibody production is outsourced, but the Shared Resource personnel are in charge of processing and distribution of samples, thus reducing the costs and maximizing efficiency. The Shared Resource also tests and implements new techniques, reagents, and assay improvements related to the different stages of antibody production.
The Antibody Shared Resource provides essential services, promotes valuable scientific and technical interactions, and stimulates cancer research that is heavily dependent on high-quality antibody reagents. These reagents help advance basic knowledge about cancer, as well as therapeutics development, and in some cases they also serve to detect and quantitate useful cancer biomarkers.
|Alexander, Joan; Kendall, Jude; McIndoo, Jean et al. (2018) Utility of Single-Cell Genomics in Diagnostic Evaluation of Prostate Cancer. Cancer Res 78:348-358|
|Huang, Yu-Han; Klingbeil, Olaf; He, Xue-Yan et al. (2018) POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. Genes Dev 32:915-928|
|Tiriac, Hervé; Belleau, Pascal; Engle, Dannielle D et al. (2018) Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov 8:1112-1129|
|Forcier, Talitha L; Ayaz, Andalus; Gill, Manraj S et al. (2018) Measuring cis-regulatory energetics in living cells using allelic manifolds. Elife 7:|
|Naguib, Adam; Mathew, Grinu; Reczek, Colleen R et al. (2018) Mitochondrial Complex I Inhibitors Expose a Vulnerability for Selective Killing of Pten-Null Cells. Cell Rep 23:58-67|
|Aberle, M R; Burkhart, R A; Tiriac, H et al. (2018) Patient-derived organoid models help define personalized management of gastrointestinal cancer. Br J Surg 105:e48-e60|
|Bhagwat, Anand S; Lu, Bin; Vakoc, Christopher R (2018) Enhancer dysfunction in leukemia. Blood 131:1795-1804|
|Khan, Jalal A; Maki, Robert G; Ravi, Vinod (2018) Pathologic Angiogenesis of Malignant Vascular Sarcomas: Implications for Treatment. J Clin Oncol 36:194-201|
|Chen, Wei-Chia; Tareen, Ammar; Kinney, Justin B (2018) Density Estimation on Small Data Sets. Phys Rev Lett 121:160605|
|Cheng, Derek; Tuveson, David (2018) Kras in Organoids. Cold Spring Harb Perspect Med 8:|
Showing the most recent 10 out of 380 publications